Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 61Carcinoma, Renal Cell 39Neoplasm Metastasis 38Neoplasms 24Kidney Neoplasms 20Neuroendocrine Tumors 19Recurrence 16Prostatic Neoplasms 15Head and Neck Neoplasms 13Tuberous Sclerosis 12Triple Negative Breast Neoplasms 12Lymphoma, Mantle-Cell 11Hodgkin Disease 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Colorectal Neoplasms 10Waldenstrom Macroglobulinemia 9Stomach Neoplasms 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Glioblastoma 9Brain Neoplasms 9Sarcoma 8Pancreatic Neoplasms 8Melanoma 8Lymphoma, Follicular 8Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8

Interventions

Cannabidiol 2Timolol 1Sirolimus 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sturge-Weber Syndrome × Everolimus × Clear all
NCT01997255 2016-05-05

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Baylor College of Medicine

Phase 2 Withdrawn

Epilepsy, Glaucoma, Sturge-Weber Syndrome, Port-Wine Stain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡